A Form 4 filed on September 4, 2026, with the SEC discloses that Peter C. Farrell, a director and chairman emeritus of ResMed Inc, sold 970 shares of ResMed common stock on September 2, 2026, under a pre-established Rule 10b5-1 trading plan.
Key Highlights
- Reporting person: Peter C. Farrell, identified in the filing as a director of ResMed Inc (NYSE:RMD).
- Shares sold: 970 shares of ResMed Common Stock disposed of on September 2, 2026.
- Sale price: $234.73 per share, according to the filing.
- Remaining ownership: 51,803 shares of ResMed Common Stock held directly following the transaction.
- 10b5-1 plan: The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025, as noted in the filing's explanation of responses.
- Ownership form: All reported shares, both sold and retained, are held directly by the reporting person.
Peter Farrell's Share Sale and Remaining Stake in ResMed
According to the filing, Peter C. Farrell, serving as a director and signing as "Chairman emeritus" of ResMed Inc, disposed of 970 shares of ResMed Common Stock on September 2, 2026, at a price of $234.73 per share. The Form 4 was signed on September 3, 2026, and filed with the SEC on September 4, 2026. The transaction is coded "S," indicating a sale, and is classified as a disposition ("D") under Table I of the form.
The filing notes that the sale was executed pursuant to a Rule 10b5-1 trading plan that Farrell adopted on August 12, 2025. Such plans allow corporate insiders to establish pre-scheduled trading arrangements at a time when they are not in possession of material non-public information. The filing also indicates the form was filed by one reporting person acting individually, not as part of a joint or group filing.
Following the reported transaction, Farrell is listed as directly beneficially owning 51,803 shares of ResMed Common Stock. No derivative securities transactions were reported in Table II of the filing. No indirect beneficial ownership positions are disclosed in connection with this transaction.
What Was Disclosed
The filing reports a sale of 970 shares of ResMed Common Stock by director Peter C. Farrell at $234.73 per share on September 2, 2026, conducted under a Rule 10b5-1 plan adopted August 12, 2025, leaving him with 51,803 directly held shares.




Please wait processing your request...